Merck’s FY sales clearly rose +17% (organic: +3%) to €15,024m, but the gross profit margin declined from 68.3% to 65.4% mainly due to the acquired business, which contributed +16% to the sales increase. EBITDA strongly rose +32% to €4,415m and net income attributable to shareholders jumped +46% to €1,629m. Operating CF was driven by the stronger operating basis and the higher D/A (+28%), partly offset by the significantly higher NWC outflow (€-1.049m after €-349
09 Mar 2017
Significant higher D/A and moderate guidance given
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Significant higher D/A and moderate guidance given
Merck KGaA (MRCK:WBO) | 0 0 1.2% | Mkt Cap: 10,792m
- Published:
09 Mar 2017 -
Author:
Martin Schnee -
Pages:
3
Merck’s FY sales clearly rose +17% (organic: +3%) to €15,024m, but the gross profit margin declined from 68.3% to 65.4% mainly due to the acquired business, which contributed +16% to the sales increase. EBITDA strongly rose +32% to €4,415m and net income attributable to shareholders jumped +46% to €1,629m. Operating CF was driven by the stronger operating basis and the higher D/A (+28%), partly offset by the significantly higher NWC outflow (€-1.049m after €-349